{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T05:27:19Z","timestamp":1736227639900,"version":"3.32.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lfs.2024.123117","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T09:11:04Z","timestamp":1729242664000},"page":"123117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical efficacy and safety of new compound single tablet antiviral drugs in the treatment of HIV\/AIDS"],"prefix":"10.1016","volume":"358","author":[{"given":"Xinyu","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyun","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"Fact sheet[EB\/OL]","author":"UNAIDS Global HIV & AIDS statistics","key":"10.1016\/j.lfs.2024.123117_bb0005"},{"issue":"3","key":"10.1016\/j.lfs.2024.123117_bb0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1056\/NEJMoa1110187","article-title":"Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy[J]","volume":"368","author":"Le","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"5322","key":"10.1016\/j.lfs.2024.123117_bb0015","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1126\/science.277.5322.112","article-title":"Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease[J]","volume":"277","author":"Autran","year":"1997","journal-title":"Science"},{"issue":"9377","key":"10.1016\/j.lfs.2024.123117_bb0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0140-6736(03)13802-0","article-title":"Decline in the AIDS and death rates in the EuroSIDA study: an observational study[J]","volume":"362","author":"Mocroft","year":"2003","journal-title":"The Lancet"},{"issue":"16","key":"10.1016\/j.lfs.2024.123117_bb0025","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1097\/QAD.0000000000000807","article-title":"Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients[J]","volume":"29","author":"Duffau","year":"2015","journal-title":"Aids"},{"issue":"4","key":"10.1016\/j.lfs.2024.123117_bb0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jphs.2018.11.016","article-title":"Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy[J]","volume":"139","author":"Luo","year":"2019","journal-title":"J. Pharmacol. Sci."},{"issue":"8","key":"10.1016\/j.lfs.2024.123117_bb0035","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/cid\/cix056","article-title":"High rates of transmission of drug-resistant HIV in Aruba resulting in reduced susceptibility to the WHO recommended first-line regimen in nearly half of newly diagnosed HIV-infected patients[J]","volume":"64","author":"Hofstra","year":"2017","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.123117_bb0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/QAI.0b013e3181af83d6","article-title":"Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders[J]","volume":"52","author":"Tozzi","year":"2009","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.lfs.2024.123117_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155145","article-title":"Adipocytokine dysregulation, abnormal glucose metabolism, and lipodystrophy in HIV-infected adolescents receiving protease inhibitors[J]","volume":"136","author":"Santiprabhob","year":"2020","journal-title":"Cytokine"},{"issue":"17","key":"10.1016\/j.lfs.2024.123117_bb0050","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32801022eb","article-title":"Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review[J]","volume":"20","author":"Brown","year":"2006","journal-title":"Aids"},{"issue":"7","key":"10.1016\/j.lfs.2024.123117_bb0055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1097\/QAD.0b013e328351f68f","article-title":"Association of tenofovir exposure with kidney disease risk in HIV infection[J]","volume":"26","author":"Scherzer","year":"2012","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.lfs.2024.123117_bb0060","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.2902","article-title":"Is there sufficient evidence for a causal association between antiretroviral therapy and diabetes in HIV-infected patients? A meta-analysis[J]","volume":"33","author":"Nduka","year":"2017","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.lfs.2024.123117_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115750","article-title":"HIV-1-specific T-cell responses and exhaustion profiles in people with HIV after switching to dual therapy vs. maintaining triple therapy based on integrase inhibitors[J]","volume":"168","author":"Mu\u00f1oz-Muela","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.lfs.2024.123117_bb0070","unstructured":"US Food and Drug Administration FDA-Approved HIV Medicines[EB\/OL] 2023-3-23, https:\/\/hivinfo.nih.gov\/understanding-hiv\/fact-sheets\/fda-approved-hiv-medicines.(Accessed 9 December 2023.)."},{"key":"10.1016\/j.lfs.2024.123117_bb0075","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2147\/PPA.S207908","article-title":"Treatment adherence and persistence among HIV-1 patients newly starting treatment[J]","volume":"13","author":"Hines","year":"2019","journal-title":"Patient Prefer. Adherence"},{"issue":"1","key":"10.1016\/j.lfs.2024.123117_bb0080","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 recommendations of the international antiviral society-USA panel[J]","volume":"329","author":"Gandhi","year":"2023","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.lfs.2024.123117_bb0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jama.2016.5945","article-title":"Genvoya: a new 4-drug combination for HIV[J]","volume":"316","year":"2016","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.lfs.2024.123117_bb0090","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1060028016660812","article-title":"Tenofovir Alafenamide[J]","volume":"50","author":"Gibson","year":"2016","journal-title":"Ann. Pharmacother."},{"year":"2017","series-title":"WHO Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy[EB\/OL]","key":"10.1016\/j.lfs.2024.123117_bb0095"},{"issue":"4","key":"10.1016\/j.lfs.2024.123117_bb0100","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults[J]","volume":"320","author":"Saag","year":"2018","journal-title":"Jama"},{"issue":"9987","key":"10.1016\/j.lfs.2024.123117_bb0105","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials[J]","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lfs.2024.123117_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-blind comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil fumarate (TDF), each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results[J]","volume":"75","author":"Arribas","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.lfs.2024.123117_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study[J]","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.lfs.2024.123117_bb0120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/QAI.0000000000001306","article-title":"Antiviral activity, safety, and pharmacokinetics of Bictegravir as 10-day monotherapy in HIV-1-infected adults[J]","volume":"75","author":"Gallant","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.lfs.2024.123117_bb0125","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable efficacy of Dolutegravir plus Lamivudine in antiretroviral treatment\u2013naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials[J]","volume":"83","author":"Cahn","year":"2020","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"issue":"10167","key":"10.1016\/j.lfs.2024.123117_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.lfs.2024.123117_bb0135","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"Van Wyk","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"12","key":"10.1016\/j.lfs.2024.123117_bb0140","first-page":"1106","article-title":"Chinese guidelines for diagnosis and treatment of HIV\/AIDS (2021 edition)[J]","volume":"60","author":"Zhi","year":"2021"},{"key":"10.1016\/j.lfs.2024.123117_bb0145","unstructured":"European AIDS Clinical Society EACS Guidelines 2023[EB\/OL] 2023, https:\/\/eacs.sanfordguide.com\/.(Accessed 9 December 2023.)."},{"issue":"7","key":"10.1016\/j.lfs.2024.123117_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25941","article-title":"HIV drug resistance in a community-randomized trial of universal testing and treatment: HPTN 071 (PopART)[J]","volume":"25","author":"Fogel","year":"2022","journal-title":"J. Int. AIDS Soc."},{"issue":"6","key":"10.1016\/j.lfs.2024.123117_bb0155","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial[J]","volume":"6","author":"Wohl","year":"2019","journal-title":"The Lancet HIV"},{"key":"10.1016\/j.lfs.2024.123117_bb0160","doi-asserted-by":"crossref","unstructured":"Sax P E, Rockstroh J K, luetkemeyer A F, et al. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically suppressed adults with human immunodeficiency virus[J]. Clin. Infect. Dis., 2021, 73(2): e485-e493. https:\/\/doi.org\/10.1093\/cid\/ciaa988.","DOI":"10.1093\/cid\/ciaa988"},{"issue":"7","key":"10.1016\/j.lfs.2024.123117_bb0165","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"The Lancet HIV"},{"issue":"8","key":"10.1016\/j.lfs.2024.123117_bb0170","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1016\/S2352-3018(20)30202-2","article-title":"Effects of first-line antiretroviral therapy on the CD4\/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study[J]","volume":"7","author":"Serrano-Villar","year":"2020","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.lfs.2024.123117_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality[J]","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.lfs.2024.123117_bb0180","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/S2352-3018(15)00006-5","article-title":"CD4\/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study[J]","volume":"2","author":"Mussini","year":"2015","journal-title":"The Lancet HIV"},{"issue":"11","key":"10.1016\/j.lfs.2024.123117_bb0185","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/infdis\/jiu669","article-title":"Course and clinical significance of CD8+T-cell counts in a large cohort of HIV-infected individuals[J]","volume":"211","author":"Helleberg","year":"2015","journal-title":"J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.lfs.2024.123117_bb0190","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1097\/QAD.0000000000001005","article-title":"CD4+\/CD8+ ratio, age, and risk of serious noncommunicable diseases in HIV-infected adults on antiretroviral therapy[J]","volume":"30","author":"Castilho","year":"2016","journal-title":"Aids"},{"issue":"6","key":"10.1016\/j.lfs.2024.123117_bb0195","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2019.09.002","article-title":"Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients[J]","volume":"54","author":"Baldin","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"10.1016\/j.lfs.2024.123117_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2311-2","article-title":"Lamivudine\/dolutegravir dual therapy in HIV-infected, virologically suppressed patients[J]","volume":"17","author":"Maggiolo","year":"2017","journal-title":"BMC Infect. Dis."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524007070?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524007070?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:37:10Z","timestamp":1736185030000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524007070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":40,"alternative-id":["S0024320524007070"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123117","relation":{},"ISSN":["0024-3205"],"issn-type":[{"type":"print","value":"0024-3205"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical efficacy and safety of new compound single tablet antiviral drugs in the treatment of HIV\/AIDS","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123117","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"123117"}}